Načítá se...
When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response
Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). Although current international guidelines for the management of CHB provide information regarding when to begin the antiviral therapy wi...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4064065/ https://ncbi.nlm.nih.gov/pubmed/24966590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i23.7207 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|